



Medical Necessity Criteria for Cycloset (Bromocriptine mesylate)

Background

Cycloset (Bromocriptine mesylate) is a dopamine agonist agent that is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings. Bromocriptine mesylate (Cycloset) is FDA-approved for use alone or in combination with other anti-diabetic drug treatments. At its August, 2011 meeting the DoD Pharmacy and Therapeutics (P & T) Committee voted to recommend Medical Necessity criteria for Cycloset.

The following criteria were established by the DoD Pharmacy & Therapeutics (P&T) Committee:

Medical Necessity Criteria for Cycloset (Bromocriptine mesylate)

All current and new users of Cycloset (Bromocriptine mesylate) must meet one of the following criteria in order for medical necessity to be approved:

1. The use of formulary alternatives is contraindicated (e.g. due to allergies, etc.).
2. The patient has experienced significant adverse effects from the formulary alternatives (e.g. hypoglycemia or lactic acidosis, etc.).

Criteria approved through the DoD P&T Committee process October 2011

www.tricare.mil is the official Web site of the
TRICARE Management Activity,
a component of the [Military Health System](#)
Skyline 5, Suite 810, 5111 Leesburg Pike,
Falls Church, VA 22041-3206

